JAM3 as a predictor in muscle-invasive bladder cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial studies a marker called JAM3 in people with muscle-invasive bladder cancer who are about to receive chemotherapy before surgery. The goal is to see if JAM3 levels can predict how well the cancer responds to treatment and what survival outcomes may be.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed diagnosis of urothelial carcinoma (a common type of bladder cancer).
- Your cancer must be muscle-invasive, meaning it has grown into the muscle layer of the bladder wall.
- You must be eligible to receive chemotherapy before surgery (neoadjuvant chemotherapy).
- The cancer must not have spread to other parts of your body (no metastases).
- You must be able to receive systemic therapy (treatment that goes throughout your body).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at tumor and blood samples from people with muscle-invasive bladder cancer to find markers that help predict how the disease will progress. It aims to improve personalized treatment for those with this specific stage of bladder cancer.
This study looks at how well certain types of bladder cancer respond to chemotherapy given before surgery. Researchers want to find markers in tumor tissue that can predict if the chemotherapy will work, so they can better tailor treatment in the future.
This trial looks at how the immune environment around a muscle-invasive bladder tumor changes after you receive treatment before surgery (neoadjuvant therapy). The goal is to understand why some tumors respond better, which could help guide future treatments.
This trial uses advanced MRI scanning to guide treatment decisions for muscle invasive bladder cancer. It aims to improve outcomes by personalizing therapy based on detailed imaging.
This trial tests a bladder-sparing approach for people with muscle-invasive bladder cancer that has a variant histology type. The goal is to avoid removing the bladder by using a combination of treatments.
This study looks at how well a standard chemotherapy given before surgery works for muscle-invasive bladder cancer. It aims to see if higher responses lead to better outcomes.
Hear when a new Urothelial Carcinoma Bladder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.